Schizophrenia is a serious mental illness that interferes with a person’s ability to think clearly, manage emotions, make decisions, and relate to others. It is a complex, long-term medical illness, affecting about one percent of Americans. Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early twenties for men, and the late twenties to early thirties for women. It is uncommon for schizophrenia to be diagnosed in a person younger than 12 or older than 40.
Schizophrenia isn’t caused by just one genetic variation, but a complex interplay of genetics and environmental influences. While schizophrenia occurs in one percent of the general population, having a history of family psychosis greatly increases the risk. Schizophrenia occurs at roughly 10% of people who have a first-degree relative with the disorder, such as a parent or sibling.
With medication, psychosocial rehabilitation, and family support, the symptoms of schizophrenia can be reduced. Typically, a health care provider will prescribe antipsychotics to relieve symptoms of psychosis, such as delusions and hallucinations. Due to a lack of awareness of having an illness and the serious side effects of medication used to treat schizophrenia, people who have been prescribed them are often hesitant to take them.
Schizophrenia is a severe mental disorder that is characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior. While schizophrenia affects about 1.1% of the population in the United States its burden in terms of health, social, and economic domains is important and affects not only patients but also family members, caregivers, and society largely due to the chronic, lifelong nature of the disease, and the frequent occurrence of relapses. With no cure for schizophrenia, the main goals of schizophrenia treatment include symptom targeting and relapse prevention.
What is Schizophrenia Market?
The market is expected to grow by factors like an increase in the patient pool, expected entry of emerging products, i.e., such as Roluperidone (MIN-101); Dexmedetomidine (BXCL501); Pimavanserin; Risperidone ISM (DORIA) and other products with deeper penetration in the 7MM markets.
Schizophrenia appears suddenly and without warning. But for most, it comes on slowly, with subtle warning signs and a gradual decline in functioning long before the first severe episode. Often, friends or family members will know early on that something is wrong, without knowing exactly what In this early phase of schizophrenia, a person may seem eccentric, unmotivated, emotionless, and reclusive to others. One may start to isolate, begin neglecting the appearance, say peculiar things, and show a general indifference to life. One may abandon hobbies and activities, and performance at work or school can deteriorate.
Also, Read- Schizophrenia Market Report
About Schizophrenia Therapy
Pharmacological therapy plays a very important role in the treatment of this disease, and several mono- and combination pharmacological therapies are available for treating schizophrenia symptoms.
Antipsychotic (AP) medications are recommended as first-line treatment for schizophrenia and are classified as first-generation antipsychotics (FGA; or typical APs) and second-generation antipsychotics (SGA; or atypical APs).
For each generation, both oral antipsychotics (OAP) and long-acting injectable therapies (LAI) are available. SGA has been proven effective in treating acute psychosis and is often preferred to FGA as they might be more effective at reducing the risk of future psychotic episodes and may also be associated with fewer extrapyramidal side effects. In practice, both FGA and SGA are used in the management of schizophrenia.
However, despite a wide range of available medications, poor AP adherence remains a key challenge in treating patients with schizophrenia and is the main driver of disease relapse. Given the importance of poor adherence and that it may, in part, explain relapses, there is a need to understand better factors that may influence adherence to AP treatment, including the choice of AP therapy.
The mechanism of action of caplyta in the treatment of schizophrenia is unknown. However, the efficacy of caplyta could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors. In November 2017, Intra-Cellular Therapies received FDA Fast Track Designation for lumateperone for the treatment of schizophrenia.
HP-3070 is an investigational asenapine-containing transdermal drug delivery system (TDDS), developed by Hisamitsu Pharmaceutical, to be applied to the skin for the treatment of schizophrenia. It is worn for 24 h to deliver the antipsychotic drug asenapine. The efficacy of the drug could be mediated through a combination of antagonism of central dopamine D2 and serotonin 5-HT2A receptors.
Original Source:- Schizophrenia Market Research Report
